These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 17237270

  • 1. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts.
    Anai S, Goodison S, Shiverick K, Hirao Y, Brown BD, Rosser CJ.
    Mol Cancer Ther; 2007 Jan; 6(1):101-11. PubMed ID: 17237270
    [Abstract] [Full Text] [Related]

  • 2. Downregulation of BCL-2 induces downregulation of carbonic anhydrase IX, vascular endothelial growth factor, and pAkt and induces radiation sensitization.
    Anai S, Shiverick K, Medrano T, Nakamura K, Goodison S, Brown BD, Rosser CJ.
    Urology; 2007 Oct; 70(4):832-7. PubMed ID: 17991582
    [Abstract] [Full Text] [Related]

  • 3. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
    Leung S, Miyake H, Zellweger T, Tolcher A, Gleave ME.
    Int J Cancer; 2001 Mar 15; 91(6):846-50. PubMed ID: 11275990
    [Abstract] [Full Text] [Related]

  • 4. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
    Anai S, Sakamoto N, Sakai Y, Tanaka M, Porvasnik S, Urbanek C, Cao W, Goodison S, Rosser CJ.
    Urol Oncol; 2011 Mar 15; 29(4):421-9. PubMed ID: 19576799
    [Abstract] [Full Text] [Related]

  • 5. (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer.
    Xu L, Yang D, Wang S, Tang W, Liu M, Davis M, Chen J, Rae JM, Lawrence T, Lippman ME.
    Mol Cancer Ther; 2005 Feb 15; 4(2):197-205. PubMed ID: 15713891
    [Abstract] [Full Text] [Related]

  • 6. Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.
    Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J.
    Clin Cancer Res; 1999 Oct 15; 5(10):2891-8. PubMed ID: 10537358
    [Abstract] [Full Text] [Related]

  • 7. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
    Gekeler V, Gimmnich P, Hofmann HP, Grebe C, Römmele M, Leja A, Baudler M, Benimetskaya L, Gonser B, Pieles U, Maier T, Wagner T, Sanders K, Beck JF, Hanauer G, Stein CA.
    Oligonucleotides; 2006 Oct 15; 16(1):83-93. PubMed ID: 16584297
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
    Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD.
    Clin Cancer Res; 2000 Jul 15; 6(7):2891-902. PubMed ID: 10914739
    [Abstract] [Full Text] [Related]

  • 10. Combination of PTEN gene therapy and radiation inhibits the growth of human prostate cancer xenografts.
    Anai S, Goodison S, Shiverick K, Iczkowski K, Tanaka M, Rosser CJ.
    Hum Gene Ther; 2006 Oct 15; 17(10):975-84. PubMed ID: 16984224
    [Abstract] [Full Text] [Related]

  • 11. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer.
    Leonetti C, Biroccio A, D'Angelo C, Semple SC, Scarsella M, Zupi G.
    Prostate; 2007 Sep 15; 67(13):1475-85. PubMed ID: 17654511
    [Abstract] [Full Text] [Related]

  • 12. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation.
    Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S, Urbanek C, Rosser CJ.
    Prostate; 2008 Aug 01; 68(11):1223-31. PubMed ID: 18465755
    [Abstract] [Full Text] [Related]

  • 13. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
    Gleave ME, Miayake H, Goldie J, Nelson C, Tolcher A.
    Urology; 1999 Dec 01; 54(6A Suppl):36-46. PubMed ID: 10606283
    [Abstract] [Full Text] [Related]

  • 14. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
    Ziegler A, Luedke GH, Fabbro D, Altmann KH, Stahel RA, Zangemeister-Wittke U.
    J Natl Cancer Inst; 1997 Jul 16; 89(14):1027-36. PubMed ID: 9230884
    [Abstract] [Full Text] [Related]

  • 15. Irradiation of human prostate cancer cells increases uptake of antisense oligodeoxynucleotide.
    Anai S, Brown BD, Nakamura K, Goodison S, Hirao Y, Rosser CJ.
    Int J Radiat Oncol Biol Phys; 2007 Jul 15; 68(4):1161-8. PubMed ID: 17637391
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of Bcl-2 enhances the efficacy of epirubicin chemotherapy in PC-3 prostate cancer cells.
    Jiang H, Xia D, Wu LJ, Chen ZD.
    Chin Med J (Engl); 2011 Dec 15; 124(23):4018-21. PubMed ID: 22340335
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Electroporation increases antitumoral efficacy of the bcl-2 antisense G3139 and chemotherapy in a human melanoma xenograft.
    Spugnini EP, Biroccio A, De Mori R, Scarsella M, D'Angelo C, Baldi A, Leonetti C.
    J Transl Med; 2011 Jul 28; 9():125. PubMed ID: 21798045
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.